Efficacy and Safety of Biosimilar Insulin Aspart (Rapilin®) Versus Originator (NovoRapid®) in Type 1 Diabetes: A Multicenter, Retrospective Cohort Study

INTRODUCTION: Data on the biosimilar insulin aspart Rapilin® ("Biosimilar") in patients with T1DM, particularly in children and adolescents, remain scarce. This study compared the real-world efficacy and safety of Biosimilar and the originator insulin aspart NovoRapid® ("Originator") in patients with type 1 diabetes mellitus (T1DM). METHODS: Electronic medical records from 34 hospitals in China covering the period from January 1, 2023 to January 31, 2026 served as the data source for this multicenter, retrospective cohort study. A total of 229 patients with T1DM who had been receiving continuous Biosimilar (n = 116) or Originator (n = 113) treatment for ≥ 12 weeks were included. The primary endpoint was the change in glycated hemoglobin (HbA1c) from baseline to the last measurement before January 31, 2026. Treatment-emergent adverse events (TEAEs) were collected and classified. RESULTS: Of the 229 included patients, 112 (48.9%) were men. The Biosimilar and the Originator groups had a mean age of 24.88 ± 17.73 years and 30.69 ± 20.84 years, respectively. The Biosimilar and the Originator groups had significant and comparable HbA1c reduction from baseline (adjusted least squares means - 1.90% vs - 1.59%; difference - 0.32%, 95% confidence interval [- 0.94%, 0.31%], P = 0.322). Furthermore, the Biosimilar group showed a marginally significant trend toward a higher HbA1c target (< 7.0%) achievement rate than the Originator group (P = 0.056). Changes in fasting blood glucose, total daily insulin dose, and daily prandial insulin dose were comparable between groups. The incidences of TEAEs (37.1% vs 38.9%), including level 1 to 3 hypoglycemia and diabetic ketoacidosis, were comparable between the Biosimilar and Originator groups. However, patients receiving Biosimilar had significantly lower incidence of injection-site reactions than patients receiving Originator (0.0% vs 5.3%, P = 0.014). CONCLUSION: Biosimilar showed comparable glycemic control, dose stability, and systemic safety to Originator in a diverse T1DM cohort containing a substantial proportion (50.0%) of pediatric and adolescent patients.

Authors

Institutions

Publication Details

Journal
Diabetes Therapy
Published
2026-11-12
DOI
https://doi.org/10.1007/s13300-026-01935-8
Primary Topic
Biosimilars and Bioanalytical Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and Safety of Biosimilar Insulin Aspart (Rapilin®) Versus Originator (NovoRapid®) in Type 1 Diabetes: A Multicenter, Retrospective Cohort Study

Ajuan Gong, Jingrui Kang, Hongwei Jiang, Xiaohong Zhang et al.
Diabetes Therapy
Biosimilars and Bioanalytical Methods
article

Efficacy and Safety of Biosimilar Insulin Aspart (Rapilin®) Versus Originator (NovoRapid®) in Type 1 Diabetes: A Multicenter, Retrospective Cohort Study

Ajuan Gong, Jingrui Kang, Hongwei Jiang, Xiaohong Zhang, Wuxing Li, Ruyi Zhong, Li Fan
article en

Abstract

INTRODUCTION: Data on the biosimilar insulin aspart Rapilin® ("Biosimilar") in patients with T1DM, particularly in children and adolescents, remain scarce. This study compared the real-world efficacy and safety of Biosimilar and the originator insulin aspart NovoRapid® ("Originator") in patients with type 1 diabetes mellitus (T1DM). METHODS: Electronic medical records from 34 hospitals in China covering the period from January 1, 2023 to January 31, 2026 served as the data source for this multicenter, retrospective cohort study. A total of 229 patients with T1DM who had been receiving continuous Biosimilar (n = 116) or Originator (n = 113) treatment for ≥ 12 weeks were included. The primary endpoint was the change in glycated hemoglobin (HbA1c) from baseline to the last measurement before January 31, 2026. Treatment-emergent adverse events (TEAEs) were collected and classified. RESULTS: Of the 229 included patients, 112 (48.9%) were men. The Biosimilar and the Originator groups had a mean age of 24.88 ± 17.73 years and 30.69 ± 20.84 years, respectively. The Biosimilar and the Originator groups had significant and comparable HbA1c reduction from baseline (adjusted least squares means - 1.90% vs - 1.59%; difference - 0.32%, 95% confidence interval [- 0.94%, 0.31%], P = 0.322). Furthermore, the Biosimilar group showed a marginally significant trend toward a higher HbA1c target (< 7.0%) achievement rate than the Originator group (P = 0.056). Changes in fasting blood glucose, total daily insulin dose, and daily prandial insulin dose were comparable between groups. The incidences of TEAEs (37.1% vs 38.9%), including level 1 to 3 hypoglycemia and diabetic ketoacidosis, were comparable between the Biosimilar and Originator groups. However, patients receiving Biosimilar had significantly lower incidence of injection-site reactions than patients receiving Originator (0.0% vs 5.3%, P = 0.014). CONCLUSION: Biosimilar showed comparable glycemic control, dose stability, and systemic safety to Originator in a diverse T1DM cohort containing a substantial proportion (50.0%) of pediatric and adolescent patients.

Diabetes Therapy
Henan University of Science and Technology (CN), Fujian Women and Children Hospital (CN), Quzhou City People's Hospital (CN), Zhumadian Central Hospital (CN), The 180th Hospital of PLA (CN), First Affiliated Hospital of Henan University of Science and Technology (CN), Second Affiliated Hospital of Anhui Medical University (CN), Second Xiangya Hospital of Central South University (CN), Quanzhou Women and Children's Hospital (CN), Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine of Hebei Province (CN)
Good health and well-being
Biosimilars and Bioanalytical Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon